Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
Olivier Govaere, Simon Cockell, Dina Tiniakos, Rachel Queen, Ramy Younes, Michèle Vacca, Leigh Alexander, Federico Ravaioli, Jeremy M. Palmer, Salvatore Petta, Jérôme Boursier, Chiara Rosso, Katherine Johnson, Kristy Wonders, Christopher P. Day, Mattias Ekstedt, Matej Orešič, Rebecca Darlay, Heather J. Cordell, Fabio Marra, Antonio Vidal‐Puig, Pierre Bédossa, Jörn M. Schattenberg, Karine Clément, Michael Allison, Elisabetta Bugianesi, Vlad Ratziu, Ann K. Daly, Quentin M. Anstee
Abstract
, whereas GDF15 supplementation tempered the inflammatory response in macrophages upon lipid loading and lipopolysaccharide stimulation. This study provides insights into the pathophysiology of progressive fibrosing steatohepatitis, and proof of principle that transcriptomic changes represent potentially tractable and clinically relevant markers of disease progression.